Schattenberg, Jörn M.
Emrich, Tilman
Funding for this research was provided by:
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Article History
Received: 29 September 2021
Revised: 5 November 2021
Accepted: 8 November 2021
First Online: 27 January 2022
Declarations
:
: The scientific guarantor of the editorial comment is Jörn M. Schattenberg, MD.
: JMS reports Consultancy: Boehringer Ingelheim, BMS, Genfit, Gilead Sciences, Intercept Pharmaceuticals, Madrigal, Merck, Novartis, Novo Nordisk, Nordic Bioscience, Pfizer, Roche, Sanofi, Siemens Healthcare GmbH.Research Funding: Gilead Sciences, Boehringer Ingelheim, Siemens Healthcare GmbH. Speakers Bureau: Falk Foundation. TE reports no conflict of interest.
: No complex statistical methods were necessary for this paper.
: Written informed consent was not required for this study because this is an editorial comment.
: Institutional review board approval was not required because this is an editorial comment.
: •Editorial Comment